At-home Leqembi in 2026 still requires clinic-based MRI monitoring for ARIA. ARIA means amyloid-related imaging abnormalities, brain swelling or tiny bleeds linked to anti-amyloid treatment. Leqembi is lecanemab-irmb for early Alzheimer's, meaning mild cognitive impairment or mild dementia due to Alzheimer's. According to the FDA, on July 13, 2026 the agency approved weekly subcutaneous Leqembi Iqlik 500 mg as two 250-mg shots for starting treatment at home without IV infusions, described in the FDA approval notice.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who can consider at-home initiation?
- What MRI schedule should you plan for?
- Why does ARIA monitoring start so early?
- What should your preparation checklist include?
Who can consider at-home initiation?
Treatment is only for adults with early Alzheimer's and confirmed amyloid-beta in the brain before starting. Confirmation requires amyloid testing ordered by the prescribing team, not symptoms alone. ApoE ε4 gene testing should come before treatment after counseling about risk and genetic-test effects.
People with two copies of ApoE ε4 have higher rates of ARIA, including symptomatic, serious, and severe events. Eisai and Biogen reported via BioSpace that an earlier autoinjector form was approved August 29, 2025 only for maintenance after 18 months of IV dosing, noted in the BioSpace press release. The 2026 change allows eligible patients to start with shots from day one. Ask the clinic whether diagnosis, amyloid result, and ApoE result are complete before setting a start date.
What MRI schedule should you plan for?
Expect a recent baseline brain MRI before the first dose. Then plan surveillance MRIs timed to early treatment, reviewed before dosing. The DailyMed label calls for MRIs within about one week before the 3rd, 5th, 7th, and 14th IV infusions, with the same approach applied to subcutaneous initiation, stated in the DailyMed label.
Keep infusion-count timing on the calendar even when taking shots, so the clinic can map each MRI to the matching treatment week. Book rides, time off, and MRI-center access in advance. Home injection saves infusion visits but does not remove these imaging visits.
Why does ARIA monitoring start so early?
ARIA-E is swelling or fluid buildup. ARIA-H is microbleeds or iron deposits on the brain surface. Most cases cause no symptoms, but some cause serious, life-threatening, or fatal events, including bleeds larger than 1 cm.
The FDA added the pre-3rd-infusion MRI in August 2025 to find ARIA-E sooner, because swelling can worsen after first detection and earlier finding guides dosing choices, explained in the FDA safety communication. That is why a normal first scan does not end monitoring. Think of early MRIs as safety checkpoints. They let the care team pause, continue, or adjust treatment before harm grows.
What should your preparation checklist include?
Use this list two to four weeks before the planned start. Keep a one-page folder with diagnosis, amyloid report, ApoE result, MRI dates, and clinic phone numbers.
Bring it to every imaging and prescribing visit. If symptoms appear, seek prompt evaluation and MRI, since symptomatic or moderate-to-severe ARIA often requires pausing doses and repeat MRI in 2 to 4 months.
- Confirm amyloid result, baseline MRI date, and who reviews scans before each dose.
- Complete ApoE ε4 testing and counseling, and record emergency contacts.
- Map MRI dates for the 3rd, 5th, 7th, and 14th dose checkpoints plus travel plans.
- Learn shot training, storage, missed-dose rules, and after-hours contact numbers.
- Assign a care partner to track headaches, confusion, dizziness, vision changes, and stroke-like signs.
You Might Also Like
- Day-One Subcutaneous Leqembi for Early Alzheimer’s in 2026: Safety and Monitoring Questions for Anti-Amyloid Treatment Patients
- The $100 Million PROTECT-Cog Alzheimer’s Study Announced in 2026: Questions People With Mild Cognitive Impairment Can Ask About the Research
- LiBBY Trial Findings for Late-Stage Dementia Agitation in 2026: Questions People With Mild Cognitive Impairment Can Ask About the Research
